Oximes can also inhibit FMS-like tyrosine kinase-3 (FLT3), which is recognized as a drug target for the treatment of acute myeloid leukemia (AML), as activating mutations of FLT3 have been found in ~30% of AML patients. The gene discussed is FLT3; the disease is acute myeloid leukemia.